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ABSTRACT
Background: Little is known about the association of cortical Aβ with depression and anxiety among
cognitively normal (CN) elderly persons.
Methods: We conducted a cross-sectional study derived from the population-based Mayo Clinic Study of
Aging in Olmsted County, Minnesota; involving CN persons aged ≥ 60 years that underwent PiB-PET
scans and completed Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI). Cognitive
diagnosis was made by an expert consensus panel. Participants were classified as having abnormal (≥1.4;
PiB+) or normal PiB-PET (<1.4; PiB−) using a global cortical to cerebellar ratio. Multi-variable logistic
regression analyses were performed to calculate odds ratios (OR) and 95% confidence intervals (95% CI)
after adjusting for age and sex.
Results: Of 1,038 CN participants (53.1% males), 379 were PiB+. Each one point symptom increase in the
BDI (OR = 1.03; 1.00–1.06) and BAI (OR = 1.04; 1.01–1.08) was associated with increased odds of PiB-
PET+. The number of participants with BDI > 13 (clinical depression) was greater in the PiB-PET+ than
PiB-PET- group but the difference was not significant (OR = 1.42; 0.83–2.43). Similarly, the number of
participants with BAI > 10 (clinical anxiety) was greater in the PiB-PET+ than PiB-PET− group but the
difference was not significant (OR = 1.77; 0.97–3.22).
Conclusions: As expected, depression and anxiety levels were low in this community-dwelling sample, which
likely reduced our statistical power. However, we observed an informative albeit weak association between
increased BDI and BAI scores and elevated cortical amyloid deposition. This observation needs to be tested
in a longitudinal cohort study.
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Introduction
Alzheimer’s disease (AD) pathology likely precedes
the development of clinical manifestations by
several years or decades (Braak and Braak, 1991;
Shaw et al., 2007). In order to study preclinical
AD, it is critical to use in vivo biomarkers such
as amyloid imaging (Dubois et al., 2007; Sperling
et al., 2011). The amyloid cascade hypothesis
posits that the accumulation of amyloid β-peptide
in the brain is a necessary component of the
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pathophysiology of AD (Hardy and Selkoe, 2002;
Choi et al., 2014). About 30% of cognitively
normal persons above the age of 70 years, 60%
of patients with mild cognitive impairment (MCI)
and 85% of clinically diagnosed AD patients are
amyloid positive (Jack et al., 2013). However,
studies have found an association between amyloid
deposition with a faster cognitive decline in both
cognitively normal elderly (Morris et al., 2009;
Chetelat et al., 2012; Knopman et al., 2012;
Petersen et al., 2016) and MCI subjects (Jack
et al., 2010; Jagust et al., 2010). A growing
body of research has shown that depressive and
anxiety symptoms may increase the risk of cognitive
decline (Geda et al., 2006, 2008, 2014; Pink
et al., 2015). Furthermore, we and others have
reported that depressive (Donovan et al., 2015;
Krell-Roesch et al., 2016) and anxiety symptoms
(Pink et al., 2017) are associated with neuroimaging
biomarkers of AD, specifically FDG-PET and
cortical thickness as measured by MRI, among
cognitively normal elderly participants. To date,
only few studies have investigated the association
between amyloid imaging and depression (Butters
et al., 2008; Chung et al., 2016; Holmes et al.,
2016; Harrington et al., 2017) or anxiety (Pietrzak
et al., 2014; Pietrzak et al., 2015; Holmes et al.,
2016). We therefore sought to examine the
association between cortical amyloid deposition,
as measured by Pittsburgh compound B positron
emission tomography (PiB-PET), depressive and
anxiety symptoms in a population-based sample of
cognitively normal participants. Given the current
discussion in the literature on whether prodromal
neuropsychiatric symptoms should be assessed
on a continuum rather than relying on arbitrary
cut-offs (Altman and Royston, 2006; Bjelland
et al., 2009; Laborde-Lahoz et al., 2014), we
used both continuous and categorical approaches
when assessing depressive and anxiety symptoms.
We hypothesized that both anxiety and depressive
symptoms would be associated with higher cortical
amyloid deposition as measured by PiB-PET in our
sample of community-dwelling cognitively normal
elderly persons.
Methods
Setting. This study was conducted in the setting
of the population-based Mayo Clinic Study of
Aging (MCSA). Details of the design and conduct
of the MCSA have been reported elsewhere
(Roberts et al., 2008). Briefly, the MCSA is an
ongoing population-based study of cognitive aging
in Olmsted County, Minnesota. Participants who
were ≥ 60 years old, had undergone brain amyloid
imaging and completed both depressive and anxiety
symptom assessments were included in this study.
The study was conducted with the approval of the
institutional review boards of the Mayo Clinic and
Olmsted Medical Center in Rochester, Minnesota
and with the written informed consent of each
participant.
Cognitive evaluation. Participants underwent
extensive evaluation including neurological ex-
amination, psychometric testing and risk factor
assessment as described in detail elsewhere
(Roberts et al., 2008). An expert consensus
panel consisting of physicians, neuropsychologists,
and nurses or study coordinators reviewed all
pertinent data and made the diagnosis of normal
cognition, MCI, or dementia. Individuals were
considered cognitively normal at baseline according
to published normative data developed on this
community (Ivnik et al., 1992a,1992b, 1992c,
1992d; Malec et al., 1992). For MCI, the following
revised Mayo Clinic criteria for MCI (Petersen,
2004; Winblad et al., 2004) were used: (1) cognitive
concern expressed by a physician, informant,
participant, or nurse; (2) impairment in one
or more cognitive domains (memory, language,
visuospatial skills, or executive functions); (3)
essentially normal functional activities; and (4)
absence of dementia. Participants with MCI had
a Clinical Dementia Rating Scale score of 0 or
0.5; however, the final diagnosis of MCI was based
on all available data. Participants with MCI or
dementia were excluded from this study.
Measurement of depressive and anxiety symp-
toms. Depressive symptoms were measured using
a validated, self-administered Beck Depressive
Inventory-II (BDI) which is a sensitive instrument
in elderly subjects (Beck et al., 1996). Thus,
the BDI-II likely captures as many depressive
symptoms as possible and we considered it to be
an appropriate screening instrument to use in a
large scale population-based study. The BDI-II
consists of 21 items such as feeling guilty and loss
of interest, that are assessed over the last two weeks
and are rated in severity on a 4-point Likert scale
ranging from 0 to 3; the total score ranges from 0
to 63. Symptoms of anxiety were measured using
the Beck Anxiety Inventory (BAI), a validated,
self-administered questionnaire (Beck et al., 1988).
Like the BDI-II, the BAI also consists of 21 items
that are assessed over the last week and measure
common symptoms of anxiety, such as nervousness
and fear of losing control. The severity of each
symptom is rated ranging from 0 to 3 with a total
score ranging from 0 to 63.
Neuroimaging of amyloid deposition. We per-
formed amyloid PET imaging using Pittsburgh
Compound B tracer. PiB scans, consisting of four
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5-minute dynamic frames, were acquired from 40
to 60 minutes after intravenous injection with
292–728 MBq (11C)PiB. Images were analyzed
using an in-house, fully automated image pro-
cessing pipeline, in which image voxel values were
extracted from automatically labeled regions of
interest propagated from an MRI template. A
global amyloid PET standardized uptake value
ratio (SUVR) was formed from the prefrontal,
orbitofrontal, parietal, temporal, anterior cingulate,
and posterior cingulate/precuneus regions of in-
terest normalized to the cerebellar grey matter.
Participants with an SUVR ≥ 1.40 were classified
as having an abnormal PiB-PET (amyloid positive;
PiB+) as we have previously validated by autopsy
(Murray et al., 2015).
Statistical Analysis. We used multi-variable lo-
gistic regression analyses to examine the association
between BDI and BAI scores with an abnormal
PiB-PET scan (PiB+ vs. PiB−, modeled on BAI,
BDI) by calculating odds ratios (OR) and 95%
confidence intervals (95% CI) after adjusting for
age and sex. Furthermore, we conducted linear
regression analyses to investigate the association
between BDI and BAI scores with elevated
amyloid deposition in the brain (PiB amyloid
SUVR modeled on BAI, BDI) by computing
β estimates, and standard errors of the mean
(SE) after adjusting for age and sex. For both
regression analyses, we treated both BDI-II and
BAI as continuous variables. In addition, we
examined BDI-II and BAI as categorical variables
with different cut-offs (BDI-II cut-offs: 4 (median
number of symptoms in the study population),
and 13 (cut-off for clinical symptoms); BAI cut-
offs: 2 (median number of symptoms in the study
population), and 10 (cut-off for clinical symptoms).
Furthermore, we conducted an analysis stratified
by four quartiles (with no symptoms being the
reference group; score = 0). Statistical testing
was done at the conventional 2-tailed alpha level
of p < 0.05. All analyses were performed using
SAS System, version 9.3 software (SAS Institute,
Cary, NC).
Results
Of 1,038 cognitively normal participants, 551
(53.1%) were males and the median age was 73
years (interquartile range, IQR 67, 79). Three
hundred and seventy nine participants (37%) were
classified as having an abnormal amyloid deposition
(PiB+). PiB+ participants were significantly older
than PiB− participants (p < 0.001). In addition,
39% of PiB+ participants were APOE ε4 carriers
whereas only 19.9% of PiB− participants were
APOE ε4 carriers (p < 0.001). There were few
participants with clinical depression (N = 63,
6.1%) or clinical anxiety (N = 51, 4.9%), and the
median BDI (3; IQR 1, 6) and BAI (1; IQR 0, 4)
scores were low. Table 1 shows the demographic
characteristics of PiB+, PiB− and total study
population. In all regression analyses, the predictor
variables (PiB+ vs. PiB− as categorical variables;
and PiB amyloid SUVR as continuous variable)
were modeled on the outcome variables (BAI and
BDI as categorical and continuous variables). The
logistic regression analysis, adjusted for age and
sex, revealed that both depression (OR = 1.03;
1.00–1.06) and anxiety (OR = 1.04; 1.01–1.08)
were associated with higher odds for an abnormal
PiB-PET when examined as continuous variables.
The association was significant for anxiety (p =
0.022) and marginally significant for depression
(p = 0.077). When we categorized BDI-II and
BAI, we observed that the odds of being PiB-
PET+ were elevated for participants with BDI ≥
13 which indicates clinical depression as compared
to participants with BDI <13 (OR = 1.42; 0.83–
2.43). The same pattern was found for participants
with BAI ≥ 10 which indicates clinical anxiety as
compared to participants with BAI <10 (OR =
1.77; 0.97–3.22). The effect sizes were smaller for
the other group comparisons (BDI: ≥ 10 vs. < 10,
≥ 4 vs. < 4; BAI: ≥ 8 vs. < 8, ≥ 2 vs. < 2). None
of these associations reached statistical significance.
The stratified analysis by quartiles also showed a
trend for higher odds with higher scores on BDI
and BAI as compared to the reference groups (score
= 0; no symptoms), however lacking statistical
significance (Table 2). When we examined the asso-
ciation between amyloid deposition as measured by
SUVR and depressive and anxiety symptoms (both
treated as numeric variables) using linear regression
analysis, we observed significant associations
between depressive symptoms (β = 0.005, SE =
0.002, p = 0.007) and amyloid deposition as well
as between anxiety symptoms (β = 0.006, SE =
0.003, p = 0.027) and amyloid deposition, after
adjusting for age and sex (Table 3).
Discussion
Here, we report the cross-sectional association
between amyloid deposition as measured by PiB-
PET and depressive and anxiety symptoms among
community-dwelling persons free of MCI or
dementia. We and others have examined the role
of neuropsychiatric symptoms in predicting the
progression from CN status to incident MCI
(Geda et al., 2014). Furthermore, an expert
panel of the Alzheimer’s Association (ISTAART
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Table 1. Demographics characteristics of study participants
P iB+ (≥1.4) P iB− (<1.4) Total
(N = 379) (N = 659) (N= 1,038)
N (%) N (%) N (%) p value
............................................................................................................................................................................................................................................................................................................................
Male 196 (51.7) 355 (53.9) 551 (53.1) 0.5031
Age (years)
Median (IQR) 77 (71, 82) 72 (65, 77) 73 (67,79) <0.0012
60–74 153 (40.4) 414 (62.8) 567 (54.6)
75–95 226 (59.6) 245 (37.2) 471 (45.4)
Education (years)
Median (IQR) 14 (12, 16) 15 (12, 17) 14 (12, 17) 0.0902
>12 Years 263 (69.4) 482 (73.1) 745 (71.8) 0.1961
BAI total (0–63)
Median (IQR) 1 (0, 4) 1 (0, 3) 1 (0, 4) 0.1122
≥10, anxiety 24 (6.3) 27 (4.1) 51 (4.9) 0.1091
≥8 38 (10.0) 52 (7.9) 90 (8.7) 0.2391
≥2, median 166 (43.8) 269 (40.8) 435 (41.9) 0.3491
Q1: 0 156 (41.2) 297 (45.1) 453 (43.6)
Q2: 1–2 84 (22.2) 157 (23.8) 241 (23.2)
Q3: 3–5 75 (19.8) 116 (17.6) 191 (18.4)
Q4: 6–36 64 (16.9) 89 (13.5) 153 (14.7)
BDI-II total (0-63)
Median (IQR) 3 (1, 7) 3 (1, 6) 3 (1, 6) 0.0052
≥13, depression 27 (7.1) 36 (5.5) 63 (6.1) 0.2801
≥10 55 (14.5) 70 (10.6) 125 (12.0) 0.0641
≥4, median 187 (49.3) 274 (41.6) 461 (44.4) 0.0151
Q1: 0 74 (19.5) 155 (23.5) 229 (22.1)
Q2: 1–2 81 (21.4) 165 (25.0) 246 (23.7)
Q3: 3–6 123 (32.5) 202 (30.7) 325 (31.3)
Q4: 7–32 101 (26.6) 137 (20.8) 238 (22.9)
PiB ratio, PVC (GMWM)
Median (IQR) 1.63 (1.45, 1.98) 1.31 (1.27, 1.34) 1.35 (1.29, 1.48) <0.0012
APOE ε4 carrier3 147 (39.0) 130 (19.9) 277 (26.9) <0.0011
Antidepressants 66 (17.4) 130 (19.7) 196 (18.9) 0.3591
IQR = interquartile range; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; PVC = partial volume correction;
GMWM = gray matter-white matter; APOE ε4 = Apolipoprotein ε4.
1 χ2 test.
2Wilcoxon rank-sum test.
3Data missing for seven participants. Antidepressant medication includes SSRI, SNRI, Tetracyclic, Tricyclic, and any other.
Neuropsychiatric Symptoms Professional Interest
Area) has also called for the systematic investigation
of emotional behavior among cognitively normal
persons (Ismail et al., 2016). When we treated
depressive and anxiety symptoms as continuous
variables, we observed an association in the
logistic regression analysis between anxiety and
an abnormal PiB-PET as well as depression and
an abnormal PiB-PET, even though the latter
was not significant. When we assessed depressive
and anxiety symptoms as categorical variables, we
observed higher effect sizes with higher scores
on BDI and BAI. The highest effect sizes
were found when we used the clinical cut-offs
(BDI ≥ 13, BAI ≥ 10). The lack of statistical
significance for this analysis may be due to low
power as only a small percentage of the PiB+
study population reported depression (7.1%) and
anxiety symptoms (6.3%). Similarly, when the
associations were stratified by quartiles of BDI-II
and BAI symptoms, we observed the same trend:
participants in quartiles reflecting higher scores
of depressive and anxiety symptoms had higher
odds for an abnormal PiB-PET. However, none
of these trends reached statistical significance. The
results of the linear regression analysis were in line
with the logistic regression analysis and revealed
a significant association between depressive and
anxiety symptoms with amyloid deposition. We also
conducted logistic and linear regression analyses
stratified by sex and APOE ε4 carrier status in
order to examine potential effects on the associ-
ation between depression, anxiety and PiB-PET
positivity. Neither sex nor APOE ε4 carrier status
significantly altered the results (data not shown).
To date, only few studies have examined the cross-
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Table 2. Logistic regression analysis on the
association between amyloid positivity with
depressive and anxiety symptoms, adjusted for age
and sex
OR (95% CI) p Value
........................................................................................................................................................
BAI total (numeric) 1.04 (1.01, 1.08) 0.022
≥10 (vs. <10) 1.77 (0.97, 3.22) 0.062
≥8 (vs. <8) 1.38 (0.87, 2.19) 0.17
≥2, median (vs. <2) 1.14 (0.87, 1.49) 0.35
Q1: 0 (reference) 0.060T
Q2: 1–2 1.02 (0.72, 1.43) 0.93
Q3: 3–5 1.27 (0.88, 1.83) 0.20
Q4: 6–36 1.40 (0.94, 2.08) 0.096
BDI-II total (numeric) 1.03 (1.00, 1.06) 0.077
≥13 (vs. <13) 1.42 (0.83, 2.43) 0.20
≥10 (vs. <10) 1.42 (0.95, 2.11) 0.084
≥4, median (vs. <4) 1.29 (0.99, 1.68) 0.058
Q1: 0 (reference) 0.046T
Q2: 1–2 1.11 (0.75, 1.66) 0.60
Q3: 3–6 1.28 (0.88, 1.86) 0.19
Q4: 7–32 1.45 (0.98, 2.14) 0.066
BAI = Beck Anxiety Inventory; BDI = Beck Depression
Inventory; Q = quartile; T = Trend; OR = Odds ratio; 95% CI =
95% confidence interval.
Table 3. Linear regression analysis on the
association between amyloid SUVR with depressive
and anxiety symptoms, adjusted for age and sex
β Est (SE) p value
........................................................................................................................................................
BAI total (continuous) 0.006 (0.003) 0.027
≥10 (vs. <10) 0.057 (0.043) 0.19
≥8 (vs. <8) 0.040 (0.033) 0.23
≥2, median (vs. <2) 0.016 (0.019) 0.39
Q1: 0 (reference) 0.066T
Q2: 1–2 0.014 (0.024) 0.55
Q3: 3–5 0.035 (0.026) 0.18
Q4: 6–36 0.045 (0.028) 0.11
BDI-II total (continuous) 0.005 (0.002) 0.007
≥13 (vs. <13) 0.057 (0.039) 0.15
≥10 (vs. <10) 0.061 (0.028) 0.034
≥4, median (vs. <4) 0.041 (0.019) 0.028
Q1: 0 (reference) <0.001T
Q2: 1–2 0.025 (0.027) 0.36
Q3: 3–6 0.051 (0.026) 0.049
Q4: 7–32 0.094 (0.028) 0.001
BAI = Beck Anxiety Inventory; BDI = Beck Depression
Inventory; Q = quartile; T = Trend; β Est = β estimate; SE =
standard error of the mean.
sectional association between amyloid deposition
and neuropsychiatric symptoms in presymptomatic
AD. For instance, in line with our findings, a
systematic review observed significant differences
in beta amyloid levels between depressed and non-
depressed older adults in the majority of included
studies (Harrington et al., 2015). In addition, the
review concluded that individuals with depression
showed higher amyloid binding on PET; however,
the review only included five studies that measured
beta amyloid using PET neuroimaging (two using
PiB, three using other ligands) (Harrington et al.,
2015). Investigators from the Australian AIBL
study recently reported that sex moderated the
relationship between amyloid deposition, APOE
genotype, and anxiety and depressive symptoms
among 423 cognitively normal elderly persons
(Holmes et al., 2016); whereas in our study,
we did not observe an altering effect of sex on
the association between anxiety and depressive
symptoms and amyloid deposition. An Australian
group also reported that anxiety significantly mod-
erated the relationship between amyloid burden
and decline in verbal and episodic memory among
178 subjects without dementia based on a cohort
analysis (Pietrzak et al., 2014). They observed that
among PiB+ participants, those with increased
anxiety symptoms had a significantly greater
decline as compared to those without increased
anxiety symptoms (Pietrzak et al., 2014). When the
study was replicated one year later with a larger
sample size of 333 participants, the researchers
again observed that anxiety symptoms but not
depressive symptoms moderated the effect of Aß-
related cognitive decline (Pietrzak et al., 2015).
This is in line with our finding, as we observed
a stronger association between amyloid deposition
and anxiety as compared to the association between
amyloid deposition and depression. Additionally,
a study derived from the AD Neuroimaging
Initiative (ADNI) database and involving MCI
patients found that Aß+ subjects that presented
with coexistent depressive symptoms had a higher
risk of developing AD at a faster conversion
rate than non-depressed counterparts. Moreover,
the amount of deposited amyloid correlated with
the rate of progression in depressed individuals
(Brendel et al., 2015). In contrast to studies that
reported a relationship between neuropsychiatric
symptoms and amyloid deposition, a study among
patients with MCI and AD failed to detect an
association between cortical amyloid deposition
and depressive symptoms (Chung et al., 2016).
Our findings may be pertinent to the recently
reported construct of mild behavioral impairment
(MBI) which is defined as a change in behavior or
personality in persons without dementia aged 50
years and older (Ismail et al., 2016). In our study,
we observed an association between depressive
and anxiety symptoms with cortical amyloid
deposition. Some of the participants may have had
a lifelong history of NPS. However, those that had
new-onset NPS after the age of 50 can be
classified as MBI; and these MBI subjects may
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have higher odds of having abnormal amyloid
deposition in the brain. Furthermore, MBI subjects
with elevated amyloid deposition may need to be
closely followed in order to determine if they are
at higher risk for developing incident dementia
as compared to MBI subjects without cortical
amyloid deposition. Previous research has shown
that PiB retention may in part be mediated by PiB
sulfation via estrogen sulfotransferase (Cole et al.,
2010), an enzyme involved in brain inflammation.
Therefore, one possible explanation of our study
findings can be an association between depressive
and anxiety symptoms and brain inflammation.
However, future research is needed to investigate
underlying mechanisms linking amyloid deposition
with depressive and anxiety symptoms. Our
findings should be interpreted in the context of the
strengths and limitations of the study. Strengths of
our study include the large scale, population-based
sample size and the categorical and continuous
assessment of depressive and anxiety symptoms.
The main limitation of this analysis was the low
number of participants with either depressive or
anxiety symptoms, even though this was expected
in this population-based study sample. This limited
our power to detect associations between depressive
and anxiety symptoms with elevated amyloid PET
SUVR. Another limitation of the study is that both
BAI and BDI-II are self-reported questionnaires,
thus we cannot rule out recall bias. However, both
assessments are widely used for clinical research
purpose. Also, as in any cross-sectional study, the
direction of causality between the association of
amyloid deposition and depression and anxiety is
unknown. In summary, we observed an informative
albeit weak association between increased BDI
and BAI scores and elevated cortical amyloid
deposition. This observation needs to be tested by
a longitudinal cohort study.
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